Does Oscar Health Cover Forteo (Teriparatide)?

What Is Forteo and Why Does It Require Special Coverage Review?

Forteo is not a typical oral bone pill. It is a daily self-injected synthetic fragment of parathyroid hormone indicated for adults with osteoporosis at very high fracture risk. The FDA approved teriparatide in 2002 for postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis 1.

Why Insurers Treat It Differently From Bisphosphonates

Most osteoporosis drugs, including alendronate and risedronate, cost under $30 per month as generics and face minimal coverage hurdles. Forteo's wholesale acquisition cost runs roughly $3,200 to $3,500 per 28-day cartridge, placing it firmly in the specialty-drug category that Oscar, like most insurers, manages through utilization controls.

Because bisphosphonates reduce vertebral fracture risk by roughly 40 to 70 percent at a fraction of the price 2, insurers almost always require documented failure of, or contraindication to, at least one antiresorptive agent before approving an anabolic drug. This is the step-therapy requirement members encounter most often.

FDA-Approved Indications That Oscar Reviews

Oscar's medical policy teams check whether the diagnosis code and clinical notes match at least one of the following FDA-labeled indications:

• Postmenopausal women with osteoporosis at high fracture risk (T-score at or below -2.5 with a fracture, or T-score at or below -3.0 alone)
• Men with primary or hypogonadal osteoporosis at high fracture risk
• Men and women with glucocorticoid-induced osteoporosis (receiving at least 5 mg prednisone equivalent per day for 3 or more months)

The 2020 AACE/ACE Clinical Practice Guidelines state: "For patients at very high risk for fracture, anabolic therapy with teriparatide, abaloparatide, or romosozumab is preferred over antiresorptive agents as initial therapy." 3 Meeting one of these definitions in the chart is the clinical anchor for any prior authorization submission.

How Oscar Health Structures Its Formulary for Forteo

Tier Placement and Cost Sharing

Oscar uses a tiered formulary across its HMO, PPO, and ACA marketplace plans. Forteo appears on Specialty Tier 4 or Tier 5 in virtually all plan designs reviewed for plan year 2024 and 2025. Specialty tiers carry coinsurance of 20 to 40 percent rather than a flat copay, which translates to $640 to $1,400 per month even after the deductible is met on many plans.

The Bonsity biosimilar (teriparatide-tbo, Radius Health) received FDA designation as interchangeable with Forteo in 2023 4. Oscar plans may place Bonsity on a lower specialty tier. If your prescriber has written "Forteo," ask whether substituting Bonsity could reduce your tier or coinsurance rate.

Specialty Pharmacy Routing

Oscar routes specialty medications, including teriparatide, through its contracted specialty pharmacy network. Filling at a retail pharmacy almost always results in a claim denial or a substantially higher cost share. Confirm the specialty pharmacy name on your Summary of Benefits and Coverage before submitting the prescription.

Out-of-Pocket Maximums and Accumulator Programs

ACA-compliant Oscar plans cap individual out-of-pocket spending at $9,450 in 2025. Teriparatide copay cards from Eli Lilly may not count toward your deductible or out-of-pocket maximum under accumulator adjustment programs. Call Oscar's member services line (on the back of your insurance card) and ask specifically whether manufacturer copay assistance counts toward your accumulator before relying on it for budget planning.

Prior Authorization for Forteo Through Oscar Health

Required Documentation

Oscar's specialty drug prior authorization forms for anabolic osteoporosis agents generally ask for:

1. A DEXA scan report showing T-score at or below -2.5, or clinical vertebral fracture documented by imaging
2. Prescriber attestation of high or very high fracture risk, referencing FRAX 10-year major osteoporotic fracture probability (threshold commonly cited: 20 percent or higher major fracture, 3 percent or higher hip fracture) 5
3. Documentation of an adequate trial of an antiresorptive agent (typically 12 months of alendronate, risedronate, ibandronate, or denosumab) OR a documented contraindication such as esophageal stricture, severe renal impairment (eGFR <35 mL/min/1.73m²), or inability to remain upright for 30 minutes
4. Confirmation that the patient has not received more than 24 cumulative months of teriparatide or abaloparatide previously
5. Prescriber's NPI and specialty (endocrinology, rheumatology, or primary care with documented osteoporosis management experience)

Timeline and Appeals

Oscar is required by most state insurance regulations and ACA rules to respond to standard prior authorization requests within 3 business days and urgent requests within 24 to 72 hours. If the initial request is denied, the formal internal appeal must be filed within the timeframe specified in the denial letter, typically 60 to 180 days. A peer-to-peer call between the treating physician and Oscar's medical reviewer resolves many borderline denials, particularly when the prescriber can cite the AACE 2020 "very high risk" category directly.

If the internal appeal fails, members have the right to an external independent review through their state's insurance commissioner. In a 2021 Commonwealth Fund analysis of ACA marketplace denials, external reviewers overturned internal denials at rates approaching 40 percent for specialty drugs in the musculoskeletal category 6.

Clinical Evidence Supporting Teriparatide Coverage

Fracture Prevention Trial (FPT)

The registration trial for teriparatide, published in the New England Journal of Medicine in 2001, enrolled 1,637 postmenopausal women with prior vertebral fracture. Subcutaneous teriparatide 20 mcg daily for a median of 21 months reduced new vertebral fractures by 65 percent (relative risk 0.35, 95% CI 0.22 to 0.55, P<0.001) and non-vertebral fragility fractures by 53 percent compared with placebo 7. This trial is the core evidence insurers and guideline bodies cite when defining the very-high-risk population.

Male Osteoporosis Trial

A separate randomized controlled trial of 437 men with osteoporosis showed teriparatide 20 mcg daily for 11 months increased lumbar spine bone mineral density by 5.9 percent versus 0.5 percent with placebo (P<0.001) 8. Oscar's prior authorization criteria for male osteoporosis align with the approved indication confirmed in this dataset.

Glucocorticoid-Induced Osteoporosis

The GIOP indication rests on a 428-patient trial comparing teriparatide with risedronate over 18 months. Teriparatide produced significantly greater increases in lumbar spine BMD (7.2% vs. 3.4%, P<0.001) and was associated with fewer new vertebral fractures (0.6% vs. 6.1%) 9. This evidence base means GIOP patients often have a stronger prior authorization case than antiresorptive-naive postmenopausal women, given the specific clinical context.

Bone Histomorphometry and Mechanism

Teriparatide stimulates osteoblasts preferentially when given as a once-daily intermittent pulse, rather than continuously. This anabolic window, distinct from the catabolic effect of chronic PTH excess in hyperparathyroidism, produces genuine new bone formation rather than simply slowing resorption 10. Understanding this mechanism matters clinically: post-teriparatide antiresorptive therapy (typically with denosumab or a bisphosphonate) is essential to preserve the BMD gains, and that transition requires its own coverage planning.

Cost Reduction Strategies When Oscar Denies or Partially Covers Forteo

Eli Lilly LillyAnswers Connect

Eli Lilly's patient-assistance program, LillyAnswers Connect, provides Forteo at no cost to uninsured and underinsured patients meeting income criteria (generally at or below 400 percent of the federal poverty level). Commercial-plan members whose plans cover Forteo may use the Lilly Savings Card, which can reduce copay to as low as $0 per month for eligible patients. Visit Lilly's site or call 1-800-545-5979 to enroll.

Formulary Exception Request

If Oscar's formulary places Bonsity lower than Forteo and your prescriber has a clinical reason to prefer branded Forteo (such as patient-specific device-handling concerns), a formulary exception request submitted with supporting documentation from the prescriber may move Forteo to the lower tier. The ACA requires Oscar to process formulary exception requests and respond within 72 hours (24 hours for urgent cases).

Step-Edit Bypass for Very High-Risk Patients

The following clinical framework describes when Oscar's step-therapy requirement can often be bypassed at initial submission rather than through appeal:

Bypass pathway 1. Documented fragility fracture (hip, vertebral, or wrist) occurring while the patient was adherent to an antiresorptive for at least 12 months. This constitutes "failure" under nearly all commercial PA criteria.

Bypass pathway 2. T-score at or below -3.5 at any site in a postmenopausal woman or man over 50, with or without fracture. Several Oscar regional plan policies list this threshold as an automatic approval criterion for anabolic therapy without a step-edit.

Bypass pathway 3. Glucocorticoid dose at or above 7.5 mg prednisone equivalent daily for at least 3 months combined with a T-score at or below -2.5. The ACR 2022 Glucocorticoid-Induced Osteoporosis Guidelines recommend anabolic therapy as preferred initial treatment in this scenario 11, and insurers increasingly honor this guidance at initial review.

Medicare Advantage vs. Commercial Plans

Oscar offers both commercial ACA plans and Medicare Advantage (MA) plans in select markets. On the Medicare side, Forteo falls under Part D (not Part B, because it is self-administered). Part D coverage gap rules changed substantially under the Inflation Reduction Act of 2022: catastrophic-phase cost sharing dropped to zero in 2024 for MA-PDP enrollees, meaning members who reach the catastrophic threshold pay nothing for Forteo for the remainder of the plan year 12. This significantly changes the math for Medicare-eligible osteoporosis patients on teriparatide.

Alternatives Oscar May Cover Instead of Forteo

If prior authorization for Forteo is denied after appeal, or while the appeal is pending, consider discussing these alternatives with the treating physician:

Abaloparatide (Tymlos)

Abaloparatide is a PTHrP analog with a similar anabolic mechanism. The ACTIVE trial (N=2,463) showed abaloparatide 80 mcg daily reduced new vertebral fractures by 86 percent versus placebo at 18 months (P<0.001) and produced non-inferior BMD gains compared with teriparatide 13. Some Oscar formularies place Tymlos on a lower specialty tier than Forteo because of contracting arrangements. Checking the specific plan's drug list for abaloparatide before submitting a PA for Forteo can save weeks of processing time.

Romosozumab (Evenity)

Romosozumab (Amgen, UCB) is a sclerostin inhibitor approved for postmenopausal women with osteoporosis at very high fracture risk. The FRAME trial (N=7,180) showed romosozumab 210 mg monthly for 12 months followed by denosumab reduced vertebral fracture risk by 73 percent versus placebo 14. Romosozumab carries an FDA boxed warning for increased cardiovascular risk. Oscar's medical policies for romosozumab differ from teriparatide policies and may have different step-therapy requirements.

Denosumab (Prolia)

Denosumab (Amgen) is an antiresorptive monoclonal antibody given as a 60 mg subcutaneous injection every 6 months. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fracture risk by 68 percent over 36 months versus placebo 15. Denosumab commonly sits on Tier 3 or a lower specialty tier on Oscar plans, and prior authorization criteria are less restrictive than for anabolic agents. For patients who cannot meet the step-therapy threshold for teriparatide, denosumab is often the path of least resistance to potent fracture protection.

What Your Prescriber Should Include in the Prior Authorization Letter

A well-written PA letter from a treating endocrinologist or rheumatologist addressing all of the following points reduces denial rates substantially:

• Patient's DEXA T-scores at lumbar spine, total hip, and femoral neck with date of scan
• FRAX 10-year fracture probability with and without BMD
• Prior fracture history with imaging confirmation if available
• Prior osteoporosis treatment history including drug name, dose, duration, and reason for discontinuation or failure
• Current glucocorticoid therapy if applicable (drug, dose, duration)
• Statement of very high fracture risk referencing AACE 2020 criteria verbatim
• Plan for post-teriparatide antiresorptive consolidation therapy (this signals to the reviewer that the prescriber understands the full treatment arc)
• Contact information for peer-to-peer review

The National Osteoporosis Foundation's Clinician's Guide notes that teriparatide is specifically appropriate for patients "with fracture history, very low BMD, or who have failed or are intolerant of other osteoporosis medications." 16 Citing published guidelines by name and year in the PA letter gives the Oscar reviewer a ready basis for approval without a peer-to-peer call.

Monitoring and the 24-Month Lifetime Limit

Why the Limit Exists

The FDA's 24-month lifetime limit on teriparatide originated from carcinogenicity data in Fischer 344 rats that developed osteosarcomas at suprapharmacological doses after long-term exposure 17. Epidemiological surveillance in humans has not confirmed elevated osteosarcoma rates at therapeutic doses, but the FDA has retained the limit. Oscar's PA approvals will specify an end date aligned with the 24-month cap.

Monitoring During Treatment

Standard monitoring during teriparatide therapy includes:

• Serum calcium and phosphorus at baseline and 1 month (risk of hypercalcemia, particularly with active vitamin D analogs)
• DEXA scan at 12 to 18 months to confirm anabolic response
• 24-hour urine calcium at baseline if pre-existing hypercalciuria is suspected
• Vitamin D 25-OH level at baseline; maintain at least 30 ng/mL throughout treatment 18

Transitioning Off Teriparatide

BMD gains from teriparatide are lost rapidly (roughly 3 to 6 percent per year) if antiresorptive therapy is not started within 1 to 3 months of the last injection 19. Oscar typically covers the transition to denosumab or a bisphosphonate with straightforward PA criteria. Plan the PA for the consolidation drug before the final teriparatide pen is used, so there is no gap in therapy.